Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer

Cancer Med. 2015 Nov;4(11):1633-8. doi: 10.1002/cam4.493. Epub 2015 Sep 2.

Abstract

The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) for non-small-cell lung cancer (NSCLC) patients. Literatures related to effects of serum CYFRA21-1 and CEA on the prognosis of lung cancer patients were retrieved from databases such as PubMed, Springer Link, Embase, Wanfang, and CNKI. Meta-analysis was carried out using RevMan 5.1 software. Ten literatures involving 1990 NSCLC patients were selected in this study. Total survive estimation merging hazard ratio (HR) in all NSCLC patients with high-level serum CYFRA21-1 was 1.64 (95% CI 1.46-1.84, P < 0.001) and that in all NSCLC patients with high level serum CEA was 1.46 (95% CI 1.28-1.65, P < 0.001). Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable.

Keywords: Cancer; carcinoembryonic antigen; keratins; meta-analysis; non-small-cell lung cancer; prognosis.

Publication types

  • Meta-Analysis

MeSH terms

  • Antigens, Neoplasm / blood*
  • Biomarkers, Tumor*
  • Carcinoembryonic Antigen / blood*
  • Carcinoma, Non-Small-Cell Lung / blood*
  • Carcinoma, Non-Small-Cell Lung / mortality*
  • Female
  • Humans
  • Keratin-19 / blood*
  • Lung Neoplasms / blood*
  • Lung Neoplasms / mortality*
  • Male
  • Prognosis
  • Proportional Hazards Models
  • Publication Bias

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Keratin-19
  • antigen CYFRA21.1